Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary - Thomson StreetEvents

Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary

Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary - Thomson StreetEvents
Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary
Published Jan 19, 2022
10 pages (5150 words) — Published Jan 19, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of EXAS.OQ conference call or presentation 19-Jan-22 4:00pm GMT

  
Brief Excerpt:

...A. Highlights: Co. released promising data on 01/18/2022 at ASCO GI demonstrating the power of EXAS second-generation Cologuard test, which Co. is calling Cologuard 2.0. 1. 2. EXAS team has made incredible progress towards providing an even better colorectal cancer screening option for patients and healthcare providers. 3. Through continuous innovation with partners at Mayo Clinic, Co. discovered new biomarkers to improve Cologuard test performance and patient experience. 4. Results discussed will highlight progress Co. has made towards achieving goals for Cologuard 2.0 which are to: a. Improved specificity, or the false positive rate. b. Improved precancer sensitivity. c. Maintain cancer sensitivity....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Exact Sciences Corp
Ticker
EXAS.OQ
Time
4:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst : Good to see that sensitivity for APL high-grade dysplasia of 83% was higher than DeeP-C, which was 69%, I believe. But that's lower than the same sensitivity in the 2012 validation study, where the metric was 86%, whereas overall APL detection of 57% was identical to this. So are there any reason, I guess, why the metric would be lower in this study? And I guess, do you expect the BLUE-C high-grade dysplasia sensitivity will be lower than DeeP-C? And overall, I mean, how important is the high-grade dysplasia sensitivity from like a clinical utility perspective? We know we have some individuals with medical backgrounds on the line. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Table Of Contents

Exact Sciences Corp at Citi Healthcare Conference (Virtual) Transcript – 2022-02-23 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 23-Feb-22 7:45pm GMT

Exact Sciences Corp Q4 2021 Earnings Call Summary – 2022-02-22 – US$ 54.00 – Edited Brief of EXAS.OQ earnings conference call or presentation 22-Feb-22 10:00pm GMT

Exact Sciences Corp Q4 2021 Earnings Call Transcript – 2022-02-22 – US$ 54.00 – Edited Transcript of EXAS.OQ earnings conference call or presentation 22-Feb-22 10:00pm GMT

Exact Sciences Corp at SVB Leerink Global Healthcare (Virtual) Transcript – 2022-02-18 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 18-Feb-22 6:40pm GMT

Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Transcript – 2022-01-19 – US$ 54.00 – Edited Transcript of EXAS.OQ conference call or presentation 19-Jan-22 4:00pm GMT

Exact Sciences Corp at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-12 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 12-Jan-22 10:15pm GMT

Exact Sciences Corp at Evercore ISI HealthCONx Virtual Conference Transcript – 2021-11-30 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 30-Nov-21 4:20pm GMT

Exact Sciences Corp at Jefferies London Healthcare Conference (Virtual) Transcript – 2021-11-16 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 16-Nov-21 3:40pm GMT

Exact Sciences Corp at Stifel Healthcare Conference (Virtual) Transcript – 2021-11-16 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 16-Nov-21 8:20pm GMT

Exact Sciences Corp Q3 2021 Earnings Call Summary – 2021-11-02 – US$ 54.00 – Edited Brief of EXAS.OQ earnings conference call or presentation 2-Nov-21 9:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary" Jan 19, 2022. Alacra Store. May 17, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Exact-Sciences-Corp-to-Discuss-Results-of-the-Second-Generation-Cologuard-Study-Call-B15095871>
  
APA:
Thomson StreetEvents. (2022). Exact Sciences Corp to Discuss Results of the Second-Generation Cologuard Study Call Summary Jan 19, 2022. New York, NY: Alacra Store. Retrieved May 17, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Exact-Sciences-Corp-to-Discuss-Results-of-the-Second-Generation-Cologuard-Study-Call-B15095871>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.